Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Automata raises $50 million for its life science research automation tech

By Chris Newmarker | February 22, 2022

AutomataAutomata (London) announced today that it has raised $50 million in Series B funding to support its automation systems for life science research.

Octopus Ventures led the round, with participation from returning investors Hummingbird, Latitude Ventures, ABB Technology Ventures and Isomer Capital, and strategic investors such as In-Q-Tel.

Company officials plan to use the money to enable significant development in the U.K. and beyond of Automata Labs for scientists working in the diagnostic, drug discovery and biotech spaces.

Automata’s technology is meant to shorten scientists’ turnaround times by scaling capacities, allowing them to spend more time on their analyses.

The company has seen scientists and clinicians conduct nearly a million tests with its technology in recent months. The U.K.’s National Health Service has been using Automata’s systems in its pathology labs to help meet diagnostic backlogs and upscale capacity, with one lab running 40 fully automated stations 24/7.

“We are thrilled to see our users adopt automation at a scale that transforms their ability to deliver more innovation in the life sciences to ultimately accelerate their pursuit of progress,” Automata CEO Mostafa ElSayed said in a news release.

“For far too long, scientists and clinicians have been having to work with overly complex lab solutions: equipment and software are disjointed and difficult to orchestrate, while solutions are often too rigid and inappropriate for labs with small geographic footprints. Our next-generation technology solves this.”


Filed Under: clinical trials, Drug Discovery, RD
Tagged With: Automata
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50